Apertus Pharmaceuticals Overview

  • Founded
  • 2011
  • Status
  • Private
  • Employees
  • 5
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $170K
Latest Deal Amount
  • Investors
  • 1

Apertus Pharmaceuticals General Information


Provider of pharmaceutical manufacturing and analytical services. The company provides controlled substance APIs, non controlled substance APIs and intellectual property to the pharmaceutical market.

Contact Information

Ownership Status
Privately Held (no backing)
Financing Status
Primary Industry
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • 331 Consort Drive
  • Ballwin, MO 63011
  • United States
+1 (866) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Apertus Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Grant 01-Jan-2011 $170K Completed Startup
To view Apertus Pharmaceuticals’s complete valuation and funding history, request access »

Apertus Pharmaceuticals Executive Team (3)

Name Title Board Seat Contact Info
Rick Ryan Ph.D Chief Executive Officer
David Gindelberger Chief Scientific Officer
Denise Heinz Manager, Operations
To view Apertus Pharmaceuticals’s complete executive team members history, request access »

Apertus Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Apertus Pharmaceuticals Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BioGenerator Venture Capital Minority 000 0000 000000 0
To view Apertus Pharmaceuticals’s complete investors history, request access »